UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~October~~January 117, ~~2007~~2008

SYNVISTA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-16043		13-3304550
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

221 West Grand Avenue

Montvale, New Jersey 07645

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (201) 934-5000

___________________________________

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 81.01 ENTRY INTO ~~OTHER~~A ~~EVENTS~~MATERIAL DEFINITIVE AGREEMENT.

On ~~October~~ January 117, ~~2007~~2008, Synvista Therapeutics, Inc., a Delaware corporation (the “Company”), ~~announced~~entered ~~that~~into ~~Dr.~~a ~~Carl~~License ~~Mendel,~~Agreement ~~MD, has joined~~ (the ~~Company~~“Agreement”) aswith ~~its~~Novel ~~Vice~~ Therapeutic ~~President~~Technology ofInc. ~~Clinical~~(“NTT”). ~~Development~~The ~~and~~Agreement ~~Chief~~provides ~~Medical~~that ~~Officer,~~NTT ~~commencing~~will ~~on October~~ develop 1,a ~~2007.~~formulation ~~Dr.~~of ~~Mendel~~the ~~will~~Company’s ~~receive~~product ancandidate ~~annual~~ALT-2074. ~~salary~~The ofAgreement provides ~~$265,000~~that ~~and~~ NTT will be grant ~~eligible~~the toCompany ~~receive~~ an ~~annual~~exclusive ~~cash~~worldwide ~~bonus~~license ~~based~~to onthe ~~predetermined~~product ~~milestones~~formulation ~~of up~~ developed tounder ~~20%~~the ofAgreement ~~his~~and ~~annual~~to ~~salary.~~the Inintellectual ~~addition,~~property ~~upon~~rights ~~commencement~~resulting under ofthe ~~his~~Agreement ~~employment~~. ~~with~~ The Agreement provides that the Company, ~~Dr. Mendel~~ will bemake ~~granted~~specified ~~options~~payments to ~~purchase~~NTT ~~70,000 shares~~upon the occurrence of certain milestone events in the ~~Company’s~~clinical ~~common~~development ~~stock~~of atthe product anformulated ~~exercise~~under ~~price~~the ~~equal~~Agreement. toIn addition, the ~~closing~~Company ~~price~~would ofalso ~~the~~ have to ~~common~~pay ~~stock~~NTT royalties on ~~the~~any ~~grant~~sales ~~date.~~of ~~Dr.~~the ~~Mendel~~developed ~~will~~product beand ana ~~at-will~~separate fee ~~employee~~if any of the rights granted under the Agreement are sublicensed by the Company.

AThe ~~copy~~license granted under the Agreement will be terminated upon the earlier to occur of (i) the date the Company notifies NTT that it does not intend to proceed further with development of formulation of ALT-2074 subject to the ~~press~~Agreement, (ii) ~~release~~the ~~announcing~~date ~~Dr.~~the ~~Mendel~~Company notifies NTT that it does not intend to continue to commercialize the products developed pursuant to the Agreement, and (iii) the later of (a) the expiration of the last valid patent covering the formulation of the Company’s ~~appointment~~intellectual isproperty ~~attached~~pursuant ~~hereto~~to asthe Agreement, which, absent the ~~Exhibit~~Agreement, ~~99.1~~would ~~and~~infringe ~~incorporated~~an ~~herein~~existing bypatent, ~~reference~~or (b)15 years from the date of the first commercial sale of a product pursuant to the Agreement.

~~ITEM~~The ~~9.01~~Agreement ~~FINANCIAL~~will ~~STATEMENTS~~be ~~AND~~filed ~~EXHIBITS~~as an exhibit to our Quarterly Report on Form 10-Q for the quarter ending March 31, 2008.

The Press Release announcing the entry into the Agreement is attached hereto as Exhibit 99.1.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits.

99.1 Press Release dated October 1, 2007.

Exhibit Number	Description

99.1	Press Release dated January 17, 2008

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SYNVISTA THERAPEUTICS, INC.
Dated: October 1, 2007	By:	/s/ Noah Berkowitz, M.D., Ph.D.
Dated: January 23, 2008	/s/ Noah Berkowitz
	Noah Berkowitz, M.D., Ph.D.	~~Noah Berkowitz, M.D., Ph.D.~~
	President and Chief Executive Officer	~~President and Chief Executive Officer~~

EXHIBIT INDEX

Exhibit Number Description

Exhibit Number	Description


99.1	Press Release dated January 17, 2008

99.1 Press Release dated October 1, 2007.

Filing Compare · Synvista Therapeutics, Inc.